143 related articles for article (PubMed ID: 10026868)
1. Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects.
Whiteside TL
Adv Exp Med Biol; 1998; 451():167-71. PubMed ID: 10026868
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms responsible for signaling and functional defects.
Reichert TE; Rabinowich H; Johnson JT; Whiteside TL
J Immunother; 1998 Jul; 21(4):295-306. PubMed ID: 9672851
[TBL] [Abstract][Full Text] [Related]
3. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma.
Reichert TE; Strauss L; Wagner EM; Gooding W; Whiteside TL
Clin Cancer Res; 2002 Oct; 8(10):3137-45. PubMed ID: 12374681
[TBL] [Abstract][Full Text] [Related]
4. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma.
Lai P; Rabinowich H; Crowley-Nowick PA; Bell MC; Mantovani G; Whiteside TL
Clin Cancer Res; 1996 Jan; 2(1):161-73. PubMed ID: 9816103
[TBL] [Abstract][Full Text] [Related]
5. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy.
Rabinowich H; Banks M; Reichert TE; Logan TF; Kirkwood JM; Whiteside TL
Clin Cancer Res; 1996 Aug; 2(8):1263-74. PubMed ID: 9816296
[TBL] [Abstract][Full Text] [Related]
6. Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma.
Dworacki G; Meidenbauer N; Kuss I; Hoffmann TK; Gooding W; Lotze M; Whiteside TL
Clin Cancer Res; 2001 Mar; 7(3 Suppl):947s-957s. PubMed ID: 11300496
[TBL] [Abstract][Full Text] [Related]
7. T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present.
Wang Q; Stanley J; Kudoh S; Myles J; Kolenko V; Yi T; Tubbs R; Bukowski R; Finke J
J Immunol; 1995 Aug; 155(3):1382-92. PubMed ID: 7636203
[TBL] [Abstract][Full Text] [Related]
8. The human natural killer cell receptor for major histocompatibility complex class I molecules. Surface modulation of p58 molecules and their linkage to CD3 zeta chain, Fc epsilon RI gamma chain and the p56lck kinase.
Bottino C; Vitale M; Olcese L; Sivori S; Morelli L; Augugliaro R; Ciccone E; Moretta L; Moretta A
Eur J Immunol; 1994 Oct; 24(10):2527-34. PubMed ID: 7523145
[TBL] [Abstract][Full Text] [Related]
9. Activation of T cells via CD55: recruitment of early components of the CD3-TCR pathway is required for IL-2 secretion.
Tosello AC; Mary F; Amiot M; Bernard A; Mary D
J Inflamm; 1998; 48(1):13-27. PubMed ID: 9368189
[TBL] [Abstract][Full Text] [Related]
10. MHC class I ligation of human T cells activates the ZAP70 and p56lck tyrosine kinases, leads to an alternative phenotype of the TCR/CD3 zeta-chain, and induces apoptosis.
Skov S; Bregenholt S; Claesson MH
J Immunol; 1997 Apr; 158(7):3189-96. PubMed ID: 9120273
[TBL] [Abstract][Full Text] [Related]
11. Engagement of the natural killer cell IgG Fc receptor results in tyrosine phosphorylation of the zeta chain.
O'Shea JJ; Weissman AM; Kennedy IC; Ortaldo JR
Proc Natl Acad Sci U S A; 1991 Jan; 88(2):350-4. PubMed ID: 1703295
[TBL] [Abstract][Full Text] [Related]
12. The effect of peripheral blood lymphocyte stimulation on zeta chain expression and IL-2 production in Hodgkin's disease.
Frydecka I; Boćko D; Kosmaczewska A; Ciszak L; Morilla R
Br J Cancer; 2001 May; 84(10):1339-43. PubMed ID: 11355944
[TBL] [Abstract][Full Text] [Related]
13. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
14. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity.
Kono K; Salazar-Onfray F; Petersson M; Hansson J; Masucci G; Wasserman K; Nakazawa T; Anderson P; Kiessling R
Eur J Immunol; 1996 Jun; 26(6):1308-13. PubMed ID: 8647210
[TBL] [Abstract][Full Text] [Related]
15. Reconstitution of deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus.
Nambiar MP; Fisher CU; Warke VG; Krishnan S; Mitchell JP; Delaney N; Tsokos GC
Arthritis Rheum; 2003 Jul; 48(7):1948-55. PubMed ID: 12847689
[TBL] [Abstract][Full Text] [Related]
16. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.
Gastman BR; Atarshi Y; Reichert TE; Saito T; Balkir L; Rabinowich H; Whiteside TL
Cancer Res; 1999 Oct; 59(20):5356-64. PubMed ID: 10537320
[TBL] [Abstract][Full Text] [Related]
17. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes.
Kim JW; Wieckowski E; Taylor DD; Reichert TE; Watkins S; Whiteside TL
Clin Cancer Res; 2005 Feb; 11(3):1010-20. PubMed ID: 15709166
[TBL] [Abstract][Full Text] [Related]
18. CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs.
Agrawal S; Marquet J; Delfau-Larue MH; Copie-Bergman C; Jouault H; Reyes F; Bensussan A; Farcet JP
J Clin Invest; 1998 Nov; 102(9):1715-23. PubMed ID: 9802885
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance.
Hoffmann TK; Dworacki G; Tsukihiro T; Meidenbauer N; Gooding W; Johnson JT; Whiteside TL
Clin Cancer Res; 2002 Aug; 8(8):2553-62. PubMed ID: 12171883
[TBL] [Abstract][Full Text] [Related]
20. Immunologic effector cells in head and neck cancer.
Vitolo D; Letessier EM; Johnson JT; Whiteside TL
J Natl Cancer Inst Monogr; 1992; (13):203-8. PubMed ID: 1356393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
